However, there is no report of the utility of skin biopsies in the diagnosis of trabectedin extravasation” Yoshimi et al (2017).
“Trabectedin is an alkylating antitumor agent. Studies have reported that trabectedin causes serious tissue injury. However, there is no report of the utility of skin biopsies in the diagnosis of trabectedin extravasation.
ReTweet if useful… Case report examines the differential diagnosis of trabectedin extravasation https://ctt.ec/kAQb5+ @ivteam #ivteam
A 51-year-old man with multiple metastases from a malignant solitary fibrous tumor of the thigh received trabectedin. A central venous port (CVP) was implanted in the left subclavian subcutaneous fat the day before chemotherapy. We noticed that the patient’s clothes were wet 18h after administration; however, redness, swelling and pain were not noted.
Therefore, the needle was reinserted and trabectedin administration was continued. The patient developed redness around the CVP and visited the emergency room 4 days after chemotherapy.” Yoshimi et al (2017).
Yoshimi, K., Was a, J., Otsuka, M., Yoshikawa, S., Goto, H., Omodaka, T., Katagiri, H., Murata, H., Hosaka, S. and Kiyohara, Y. (2017) Differential diagnosis of trabectedin extravasation: A case report. The Journal of Dermatology. April 9th. [Epub ahead of print].
Thank you to our partners for supporting IVTEAM